Subtype
Malignant Colorectal Neoplasm
CI-CAN-00005874Explore in graph →
1,565 active trials21 approved drugs382 evidence items
- NCIt
- C4978
- DOID
- 9256
- Other
- 1 more code
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00005874Explore in graph →
Clinical trials
7,296 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (722)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07811453 | Liver Transplantation for Non-Resectable Colorectal Liver Metastases Without Local Treatment Options(GTO-001) | not yet recruiting | N/A | 260 | Charite University, Berlin, GermanyOTHER | 1 | Sep 10, 2026 | clinicaltrials |
| NCT07812805 | SKL35501 With SKL35502 Imaging in Adults With NTSR1 Positive Advanced Solid Tumors | recruiting | Phase 1 | 100 | SK Life Science, Inc.INDUSTRY | 2 | Sep 10, 2026 | clinicaltrials |
| NCT03803553 | Identification and Treatment Of Micrometastatic Disease in Stage III Colon Cancer | active not recruiting | Phase 3 | 400 | Massachusetts General HospitalOTHER | 1 | Sep 9, 2026 | clinicaltrials |
| NCT04899908 | Stereotactic Brain-directed Radiation With or Without Aguix Gadolinium-Based Nanoparticles in Brain Metastases | recruiting | Phase 2 | 134 | Brigham and Women's HospitalOTHER | 1 | Sep 9, 2026 | clinicaltrials |
| NCT06253871 | A Phase 1/1b Study of IAM1363 in HER2 Cancers | recruiting | Phase 1 | 383 | Iambic Therapeutics, IncINDUSTRY | 8 | Sep 9, 2026 | clinicaltrials |
| NCT06440005 | A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors | recruiting | Phase 1 | 80 | Angiex, Inc.INDUSTRY | 1 | Sep 9, 2026 | clinicaltrials |
| NCT06501482 | Adjuvant FOLFIRI Based-chemotherapy After Resection of CLM Responding to Preoperative FOLFIRI(IRIMAD) | recruiting | Phase 3 | 254 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Sep 9, 2026 | clinicaltrials |
| NCT06578559 | Phase II Study of ctDNA-guided Encorafenib Plus Cetuximab Retreatment in Patients BRAF V600E Mutated mCRC(BRICKET) | active not recruiting | Phase 2 | 16 | Gruppo Oncologico del Nord-OvestOTHER | 1 | Sep 9, 2026 | clinicaltrials |
| NCT06625775 | Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors | recruiting | Phase 1 | 392 | TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)INDUSTRY | 6 | Sep 9, 2026 | clinicaltrials |
| NCT06696768 | Clinical Trial of an Anti-cancer Drug, CA-4948 (Emavusertib), in Combination With Chemotherapy Treatment (FOLFOX Plus Bevacizumab) in Metastatic Colorectal Cancer | recruiting | Phase 1 | 24 | National Cancer Institute (NCI)NIH | 1 | Sep 9, 2026 | clinicaltrials |
| NCT06699836 | CLOVER - CCR5-targeting Leronlimab With Oral Chemotherapy and VEGF-inhibitor Enriched Regimen(CLOVER) | active not recruiting | Phase 2 | 66 | CytoDyn, Inc.INDUSTRY | 1 | Sep 9, 2026 | clinicaltrials |
| NCT07147231 | Testing the Effectiveness of the Anti-cancer Drug Pidnarulex (CX-5461), in Combination With Another Anti-cancer Drug Cemiplimab (REGN2810), in Treating Refractory Microsatellite Stable Colorectal Cancer | recruiting | Phase 1 / Phase 2 | 86 | National Cancer Institute (NCI)NIH | 1 | Sep 9, 2026 | clinicaltrials |
| NCT07341217 | Chemo Brain Prehab Project(CHEMOBRAIN) | recruiting | N/A | 86 | Dr. Chris GaffneyOTHER | 1 | Sep 9, 2026 | clinicaltrials |
| NCT07549412 | A Study of Precemtabart Tocentecan With or Without Bevacizumab Compared to Trifluridine/Tipiracil Plus Bevacizumab in Participants With Previously Treated Metastatic Colorectal Cancer (PROCEADE-CRC-03) | recruiting | Phase 3 | 1,020 | EMD Serono Research & Development Institute, Inc.INDUSTRY | 16 | Sep 9, 2026 | clinicaltrials |
| NCT07805369 | A Phase 1 Study of DEM301 in Participants With Metastatic Colorectal Cancer | not yet recruiting | Phase 1 | 60 | DEM BioPharma, Inc.INDUSTRY | 0 | Sep 9, 2026 | clinicaltrials |
| NCT07809074 | Mindfulness and Self-Compassion Intervention for Ostomy Patients Due to Colorectal Cancer on Loneliness (MSC-OP)(MSC-OP) | not yet recruiting | N/A | 20 | The Hong Kong Polytechnic UniversityOTHER | 0 | Sep 9, 2026 | clinicaltrials |
| NCT07809893 | Ivosidenib Plus mFOLFOXIRI and Celecoxib for BRAF-targeted Therapy-refractory BRAF V600E-mutant Colorectal Cancer Patients | recruiting | Phase 2 | 45 | Sun Yat-sen UniversityOTHER | 1 | Sep 9, 2026 | clinicaltrials |
| NCT07810114 | Total Neoadjuvant mFOLFOX6 Plus Suvemcitug and Enlonstobart With Selective Omission of Pelvic Radiotherapy for High-Risk Mid-Rectal Locally Advanced Rectal Cancer(SPARE) | not yet recruiting | Phase 2 | 52 | Fudan UniversityOTHER | 1 | Sep 9, 2026 | clinicaltrials |
| NCT07811076 | Serine/Glycine-Restricted Diet With Chemoradiotherapy for Rectal Cancer(SG-RCT) | not yet recruiting | Phase 1 / Phase 2 | 140 | Xuelei Ma MDOTHER | 1 | Sep 9, 2026 | clinicaltrials |
| NCT07811128 | Leveraging Digital Health Solutions to Collect Patient-Reported Outcomes in Rectal Cancer | not yet recruiting | — | 150 | University of California, San FranciscoOTHER | 1 | Sep 9, 2026 | clinicaltrials |
| NCT00001823 | Evaluation for NCI Surgery Branch Clinical Research Protocols | recruiting | — | 7,000 | National Cancer Institute (NCI)NIH | 1 | Sep 8, 2026 | clinicaltrials |
| NCT02997228 | Testing the Addition of Atezolizumab to Combination Chemotherapy or Atezolizumab Alone for Metastatic Colon or Rectal Cancer, the COMMIT Study | active not recruiting | Phase 3 | 120 | National Cancer Institute (NCI)NIH | 1 | Sep 8, 2026 | clinicaltrials |
| NCT03715933 | Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas | recruiting | Phase 1 | 411 | Inhibrx Biosciences, IncINDUSTRY | 6 | Sep 8, 2026 | clinicaltrials |
| NCT04015765 | Hybrid-APC Margin Ablation to Prevent Post EMR Adenoma Recurrence(h-APC_EMR) | completed | N/A | 376 | Centre hospitalier de l'Université de Montréal (CHUM)OTHER | 1 | Sep 8, 2026 | clinicaltrials |
| NCT05984589 | Personalized Health Self-Management Training for Colorectal Cancer Survivors | recruiting | N/A | 120 | University of Southern CaliforniaOTHER | 1 | Sep 8, 2026 | clinicaltrials |
| NCT06807073 | Complete Closure After Endoscopic Mucosal Resection of Large Non-Pedunculated Colorectal Polyps(Closure-RCT) | recruiting | N/A | 686 | Centre hospitalier de l'Université de Montréal (CHUM)OTHER | 1 | Sep 8, 2026 | clinicaltrials |
| NCT07035691 | New bioMarkers tO straTIfy cOlorectal caNcer Referrals(MOTION) | recruiting | — | 582 | Queen Mary University of LondonOTHER | 1 | Sep 8, 2026 | clinicaltrials |
| NCT07228832 | Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal Cancer(HARMONi-GI3) | recruiting | Phase 3 | 600 | Summit TherapeuticsINDUSTRY | 14 | Sep 8, 2026 | clinicaltrials |
| NCT07403981 | Advocacy, Partnership, Outreach, and Yielding Optimized Care for Oncology Patients | recruiting | N/A | 60 | Stanford UniversityOTHER | 1 | Sep 8, 2026 | clinicaltrials |
| NCT07779694 | 16-Hour Fasting Plus Serplulimab and CAPEOX as Neoadjuvant Therapy in pMMR/MSS Advanced Mid-to-Low Rectal Cancer | not yet recruiting | Phase 2 | 51 | Zhejiang UniversityOTHER | 0 | Sep 8, 2026 | clinicaltrials |
| NCT07795801 | Mind-Body Sexual Well-Being Program for Female GI Cancer Survivors | not yet recruiting | N/A | 100 | Massachusetts General HospitalOTHER | 1 | Sep 8, 2026 | clinicaltrials |
| NCT07807345 | Phase 1 Study of STRO-006 in Adults With Refractory Solid Tumors That Are Recurrent or Metastatic | not yet recruiting | Phase 1 | 285 | Sutro Biopharma, Inc.INDUSTRY | 1 | Sep 8, 2026 | clinicaltrials |
| NCT07807800 | A Study of DES-1357 in People With Deficient Mismatch Repair (dMMR)/Microsatellite Instability-High (MSI-H) Metastatic Colorectal Cancer (mCRC) | not yet recruiting | Phase 1 / Phase 2 | 88 | D. E. Shaw Research, LLCINDUSTRY | 0 | Sep 8, 2026 | clinicaltrials |
| NCT07807956 | A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous ABBV-253 Moves Through the Body in Adult Participants With Advanced Solid Tumors | not yet recruiting | Phase 1 | 130 | AbbVieINDUSTRY | 0 | Sep 8, 2026 | clinicaltrials |
| NCT07808151 | Neoadjuvant Pembrolizumab and Porustobart in Resectable pMMR/MSS Colon Cancer | not yet recruiting | Phase 2 | 100 | Solstice Oncology, Inc.INDUSTRY | 6 | Sep 8, 2026 | clinicaltrials |
| NCT07808164 | ENPP1/cGAS (EG) and FAP Expression Profiles in Solid Tumors: An Immunohistochemical Study in a Vietnamese Cohort | recruiting | — | 162 | Tam Anh Research InstituteOTHER | 1 | Sep 8, 2026 | clinicaltrials |
| NCT01239082 | Colonoscopy Versus Fecal Immunochemical Test in Reducing Mortality From Colorectal Cancer (CONFIRM)(CONFIRM) | active not recruiting | N/A | 50,126 | VA Office of Research and DevelopmentFED | 2 | Sep 4, 2026 | clinicaltrials |
| NCT04427527 | Accelerating Colorectal Cancer Screening Through Implementation Science in Appalachia(ACCSIS) | completed | N/A | 29,772 | Mark Dignan, PhDOTHER | 1 | Sep 4, 2026 | clinicaltrials |
| NCT04704661 | Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial | active not recruiting | Phase 1 | 51 | National Cancer Institute (NCI)NIH | 1 | Sep 4, 2026 | clinicaltrials |
| NCT06333392 | Total Underwater Colonoscopy (TUC) for Improved Colorectal Cancer Screening: A Randomized Controlled Trial | recruiting | N/A | 1,070 | Vestre Viken Hospital TrustOTHER | 2 | Sep 4, 2026 | clinicaltrials |
| NCT06787105 | Fruquintinib in Patients With Metastatic Colorectal Cancer(FRUQUENT) | recruiting | — | 150 | iOMEDICO AGINDUSTRY | 1 | Sep 4, 2026 | clinicaltrials |
| NCT06790355 | ProSight: A Multi-centre Interventional Study Evaluating MCED in Asymptomatic Population | completed | N/A | 2,527 | Shanghai Weihe Medical Laboratory Co., Ltd.INDUSTRY | 1 | Sep 4, 2026 | clinicaltrials |
| NCT07416552 | A Study to Investigate CEA-PRIT 2.0 in Participants With Metastatic Colorectal Cancer (mCRC) | recruiting | Phase 1 | 180 | Hoffmann-La RocheINDUSTRY | 1 | Sep 4, 2026 | clinicaltrials |
| NCT07661641 | A Study of [177Lu]Lu-A9-0631 and [225Ac]Ac-A9-0642 With [68Ga]Ga-A9-6217 or [177Lu]Lu-A9-0631 Imaging in GRPR+ Solid Tumors | recruiting | Phase 1 | 115 | Alpha-9 Oncology USA Inc.INDUSTRY | 1 | Sep 4, 2026 | clinicaltrials |
| NCT07805551 | A Study of HDM2017 Combination Therapy in Advanced Colorectal Cancer | recruiting | Phase 1 / Phase 2 | 220 | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 4, 2026 | clinicaltrials |
| NCT04967183 | Polyprev: Study to Compare Fecal Immunochemical Test With Endoscopic Surveillance After Advanced Adenoma Resection in Fecal Immunochemical Test Colorectal Cancer Screening Programs. | active not recruiting | N/A | 3,788 | Fundacin Biomedica Galicia SurOTHER | 1 | Sep 3, 2026 | clinicaltrials |
| NCT05673148 | Testing the Addition of Total Ablative Therapy to Usual Systemic Therapy Treatment for Limited Metastatic Colorectal Cancer, ERASur Trial | recruiting | Phase 2 | 146 | Alliance for Clinical Trials in OncologyOTHER | 2 | Sep 3, 2026 | clinicaltrials |
| NCT06252649 | Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation(CodeBreaK 301) | recruiting | Phase 3 | 450 | AmgenINDUSTRY | 35 | Sep 3, 2026 | clinicaltrials |
| NCT06337084 | Diagnostic Efficacy and Dosimetry of MNPR-101-DFO*-89Zr in Patients With Solid Tumors | active not recruiting | Phase 1 | 12 | Monopar TherapeuticsINDUSTRY | 1 | Sep 3, 2026 | clinicaltrials |
Data updated 20 days agoSource updated Sep 10, 2026source: clinicaltrials